Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines

被引:0
|
作者
Krzysztof Koras
Ewa Kizling
Dilafruz Juraeva
Eike Staub
Ewa Szczurek
机构
[1] University of Warsaw,Faculty of Mathematics, Informatics and Mechanics
[2] Merck Healthcare KGaA,Oncology Bioinformatics, Translational Medicine
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Computational models for drug sensitivity prediction have the potential to significantly improve personalized cancer medicine. Drug sensitivity assays, combined with profiling of cancer cell lines and drugs become increasingly available for training such models. Multiple methods were proposed for predicting drug sensitivity from cancer cell line features, some in a multi-task fashion. So far, no such model leveraged drug inhibition profiles. Importantly, multi-task models require a tailored approach to model interpretability. In this work, we develop DEERS, a neural network recommender system for kinase inhibitor sensitivity prediction. The model utilizes molecular features of the cancer cell lines and kinase inhibition profiles of the drugs. DEERS incorporates two autoencoders to project cell line and drug features into 10-dimensional hidden representations and a feed-forward neural network to combine them into response prediction. We propose a novel interpretability approach, which in addition to the set of modeled features considers also the genes and processes outside of this set. Our approach outperforms simpler matrix factorization models, achieving R =\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$=$$\end{document} 0.82 correlation between true and predicted response for the unseen cell lines. The interpretability analysis identifies 67 biological processes that drive the cell line sensitivity to particular compounds. Detailed case studies are shown for PHA-793887, XMD14-99 and Dabrafenib.
引用
收藏
相关论文
共 50 条
  • [11] Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel
    Burke, Amy J.
    Ali, Husnain
    O'Connell, Enda
    Sullivan, Francis J.
    Glynn, Sharon A.
    ANTICANCER RESEARCH, 2016, 36 (02) : 633 - 641
  • [12] Cyanobacteria cell prediction using interpretable deep learning model with observed, numerical, and sensing data assemblage
    Pyo, JongCheol
    Cho, Kyung Hwa
    Kim, Kyunghyun
    Baek, Sang-Soo
    Nam, Gibeom
    Park, Sanghyun
    WATER RESEARCH, 2021, 203
  • [13] ENHANCED EFFICACY OF TUMOR TREATING FIELDS AND AURORA B KINASE INHIBITOR COMBINATION IN GLIOMA CELL LINES
    Krex, Dietmar
    Bartmann, Paula
    Temme, Achim
    Schneiderman, Rosa S.
    Voloshin, Tali
    Giladi, Moshe
    Kinzel, Adrian
    Kirson, Eilon
    Plati, Yoram
    NEURO-ONCOLOGY, 2018, 20 : 264 - 264
  • [14] Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
    Araki, J
    Okamoto, I
    Suto, R
    Ichikawa, Y
    Sasaki, J
    LUNG CANCER, 2005, 48 (01) : 141 - 144
  • [15] Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines
    Box, AH
    Demetrick, DJ
    CARCINOGENESIS, 2004, 25 (12) : 2325 - 2335
  • [16] Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
    Wang, WL
    Healy, ME
    Sattler, M
    Verma, S
    Lin, J
    Maulik, G
    Stiles, CD
    Griffin, JD
    Johnson, BE
    Salgia, R
    ONCOGENE, 2000, 19 (31) : 3521 - 3528
  • [17] Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
    Wen-Lan Wang
    Mary Ellen Healy
    Martin Sattler
    Shalini Verma
    Jeffrey Lin
    Gautam Maulik
    Charles D Stiles
    James D Griffin
    Bruce E Johnson
    Ravi Salgia
    Oncogene, 2000, 19 : 3521 - 3528
  • [18] Efficacy of B-raf and MEK inhibitor on human anaplastic thyroid cancer cell lines
    Kurata, K.
    Onoda, N.
    Noda, S.
    Kashiwagi, S.
    Asano, Y.
    Takashima, T.
    Hirakawa, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S566 - S566
  • [19] Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability
    Kim, Kyung-Ok
    Park, Woo-Jae
    Jung, YunJae
    Lee, Won-Suk
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (08) : 437 - 444
  • [20] Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
    Fink, Lauren S.
    Beatty, Alexander
    Devarajan, Karthik
    Peri, Suraj
    Peterson, Jeffrey R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (01) : 298 - 306